|| The A allele ( assumed to be T) responds better to sorafenib in HCC
|| AG as AA responds better to sorafenib during HCC treatment
|| GG genotype responds less well to sorafenib during HCC treatment
|?|| (A;A) (A;G) (G;G) ||28|
|| not reviewed
|| Insufficiently evaluated not reviewed
A preliminary study found that response to sorafenib in hepatocellular carcinoma was better and resulted in longer progression-free survival time for rs2257212 (C;T) and (T;T) patients than for those with (C;C) genotypes. SLC15A2, the gene harboring rs2257212, is a solute carrier family member that is known to be involved in drug transport.